Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure - DAPA-HF

Study identifier:D1699C00001

ClinicalTrials.gov identifier:NCT03036124

EudraCT identifier:2016-003897-41

CTIS identifier:N/A

Study Complete

Official Title

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

Medical condition

Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)

Phase

Phase 3

Healthy volunteers

No

Study drug

Dapagliflozin, Placebo

Sex

All

Actual enrollment

4744

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 08 Feb 2017
Primary Completion Date: 17 Jul 2019
Study Completion Date: 17 Jul 2019

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria